Business SML Biopharm of Korea signs MOU with Affilogic of France
By Diplomacy Journal Lee Kap-soo SML Biopharm, a South Korea-based biotech company specializing in mRNA-based therapeutics, announced on May 8 that it has signed a memorandum of understanding (MOU) with French biotechnology firm Affilogic to collaborate on the development of next-generation targeted drugs using mRNA-LNP (lipid nanoparticle) technology. The agreement aims to integrate Affilogic’s proprietary Nanofitin targeting technology with SML Biopharm’s mRNA-LNP platform. Under the MOU, the two companies will explore opportunities to combine their respective core technologies to develop in